ChrisLiu

Associate

(T) 86.21.2201.8015

Chris Liu represents industrial, commercial, and individual clients in patent litigation, inter partes reviews, trade secret, cross-border IP licensing, and patent prosecution matters.

Chris has successfully represented clients in the United States, Canada, Europe, mainland China, Hong Kong, and Taiwan in a wide variety of technologies. His experience includes consumer electronics, integrated circuit (IC) designs, semiconductor equipment, microelectronic devices and packaging, medical devices and diagnostic equipment, big data, block chain, artificial intelligence (AI), telecommunications equipment and network infrastructure, credit cards, privacy and data security, data encryption, electro-optical material and device, MEMS, mobile web, Fabry-Perot etalon, LED control circuit, tunable laser, tunable filter, fiber optics, optical coherence tomography, variable optical attenuator, hyper-spectral imaging, and fiber optic switches.

Prior to entering the legal profession, Chris conducted high-energy particle physics research at Fermilab and intracranial electroencephalography (iEEG) brain function research at Harvard Medical School and Boston Children's Hospital. He also worked as a software engineer for a major IT company and as a technical marketing specialist at a start-up company.

Chris maintains an active pro bono practice that includes working with the U.S. Court of Appeals for Veterans Claims to seek benefit improvements for veterans.

Chris is a native Mandarin speaker. He is a member of American Intellectual Property Law Association and the Asian Pacific American Bar Association. He has spoken on IP issues affecting Asian companies and on big data.

Experience

  • Celgene to be acquired by Bristol-Myers Squibb for approx. $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.